9
Dec
2021
SQZ Shows Promise With HPV+ Cancer Vaccine in Early Solid Tumor Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Dec
2021
Three Core Questions Underlying Durable Behavior Change
Each of us would be happier and healthier if we could adopt and maintain healthier behaviors. Many of us – including providers, organizational heads, community leaders, parents – hope to cultivate healthier behavior in others. The difficulty we experience attaining these common goals reflects three underlying questions around behavior change. Is the most effective locus of intervention the individual... Read More
8
Dec
2021
Newpath Partners Secures $350M for Startups Working on Hard Science Problems
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2021
Targeted Small Molecule Protein Degraders: Nello Mainolfi on The Long Run
Today’s guest on The Long Run is Nello Mainolfi. Nello is the president and CEO of Cambridge, Mass.-based Kymera Therapeutics. Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of... Read More
5
Dec
2021
Corporate Health and Wellness Has New Urgency And Vision
Like no other event in our collective experience, the pandemic reminded us of the need for an integrative view of wellbeing beyond traditional measures of physical health. Focusing exclusively on cholesterol level and bone density, for example, would be hopelessly inadequate for the needs of today. I continued to be haunted by Zak Kohane’s description of the many children’s hospitals... Read More
2
Dec
2021
The Variant on the Move
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Dec
2021
T Cell Therapies for Autoimmunity: Jeff Bluestone on The Long Run
Today’s guest on The Long Run is Jeff Bluestone. Jeff is the president and CEO of South San Francisco-based Sonoma Biotherapeutics. Jeff has a long, distinguished history as an immunology researcher at the University of Chicago and UCSF. He learned over the years how to enlarge his impact by coordinating groups of scientists as an administrator at the Immune Tolerance... Read More
1
Dec
2021
Apollo Health Ventures Gets $180M to Invest in Extending Human Healthspan
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2021
Obesity Is Rising; Can Health Coaches & Tech Drive Durable Behavior Change?
As we enter the holiday eating season – quickly followed by the New Year get-in-shape resolution season – let’s look at obesity challenge head-on. Expert physicians who study obesity recognize the condition as a complex disease associated with profound health consequences. It also represents, for many health tech entrepreneurs, a high-value problem to be solved. Obesity has been ratcheting upward... Read More
26
Nov
2021
Omicron Variant: the Latest Twist in the Pandemic
I hope you all had a wonderful Thanksgiving. My Thursday started with me waking up in anticipation of a delightful meal with family (I love apple pie with gelato), at least partially reunited for a holiday meal together after so many months of caution and precautions. I was really looking forward to not having to do much else but drink... Read More
23
Nov
2021
In RNA Therapeutics, Are Circles Better than Lines?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Nov
2021
Reviving Targeted Radiopharmaceuticals for Cancer: Ken Song on The Long Run
Today’s guest on The Long Run is Ken Song. Ken is the CEO of San Diego-based RayzeBio. At RayzeBio, Ken discovered new opportunity in an area cancer R&D that had been long ago abandoned. It’s about creating targeted cancer therapies loaded with radioactive isotopes to give them extra tumor-killing punch. These aren’t the same thing as antibody-drug conjugates, in which... Read More
18
Nov
2021
Califf Gets FDA Nod, Novo Acquires Dicerna, & a Shrewd Investment in Pittsburgh
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Nov
2021
Precision Health’s Next Great Challenge: Behavior Change
Humility may not be the first word you associate with “genetics,” “precision medicine,” and “Harvard,” but it was unquestionably the theme of the day at a fascinating panel this week convened by the Harvard Data Science Initiative. The discussion (video here), was remarkably grounded. It reflected hard-earned learnings from experts who have tried to implement data-driven, “precision” health solutions outside the... Read More
17
Nov
2021
Chroma Medicine Secures $125m to Edit the Epigenome
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Nov
2021
A Trek in the Himalayas for Cancer Research
The biotech community can do extraordinary things when fixated on a goal. Like curing cancer. I’m excited to announce today that I’m taking a team of biotech leaders on a mission to raise $1 million for cancer research at Fred Hutch. This group will come together on a trek to Everest Base Camp. It’s a legendary hike in the Himalayas... Read More
15
Nov
2021
Motivating a Modicum of Exercise: The Healthtech Opportunity
“It’s been a busy few weeks for product announcements in the world of fitness,” industry observer Anthony Vennare recently commented, citing the latest offerings from the Peloton, Mirror, Tempo, and other digital fitness platforms. On the one hand, these developments are encouraging, offering customers pursuing fitness — and who are willing and able to afford the steep premiums — a... Read More
11
Nov
2021
Pfizer’s Game-Changer, Moderna-NIH Feud Goes Public, & Genomics England Ends Dx Odysseys
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Nov
2021
UK’s 100K Genomes Study Ends Diagnostic Odyssey for Some With Rare Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Nov
2021
A Remarkable Life in Science: David Baltimore on The Long Run
Today’s guest on The Long Run is David Baltimore. David is one of the most accomplished biomedical scientists – and scientific citizens — of the past 50 years. He recently won Lasker~Koshland Award for Special Achievement. The award was granted “for the breadth and beauty of his discoveries in virology, immunology, and cancer; for his academic leadership; for his mentorship... Read More